Astrana Health, Inc. (NASDAQ:ASTH) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,264 shares of the company’s stock after selling 1,144 shares during the quarter. JPMorgan Chase & Co. owned 0.12% of Astrana Health worth $4,013,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ASTH. Principal Financial Group Inc. purchased a new position in Astrana Health during the 3rd quarter worth $13,383,000. Franklin Resources Inc. purchased a new position in Astrana Health during the third quarter worth about $1,187,000. Hohimer Wealth Management LLC purchased a new position in Astrana Health during the third quarter worth about $312,000. Geode Capital Management LLC acquired a new stake in Astrana Health in the third quarter valued at about $58,995,000. Finally, Barclays PLC purchased a new stake in Astrana Health in the 3rd quarter valued at approximately $4,457,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Price Performance

Astrana Health stock opened at $35.17 on Friday. The firm has a market capitalization of $1.98 billion, a PE ratio of 27.05, a P/E/G ratio of 1.12 and a beta of 1.20. Astrana Health, Inc. has a 52 week low of $29.08 and a 52 week high of $63.20. The firm’s 50-day simple moving average is $37.26 and its 200 day simple moving average is $46.67. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same quarter in the prior year, the firm earned $0.47 earnings per share. On average, equities research analysts predict that Astrana Health, Inc. will post 1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

ASTH has been the subject of a number of analyst reports. Truist Financial cut their target price on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. BTIG Research upped their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target for the company. Finally, Robert W. Baird boosted their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $63.67.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.